**Supplementary Table 3.** Outcome of studies using the ARCO Classification

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Nr.** | **Avg. Follow-up** | **Preoperative Staging** | **Clinical assessment tool** | **Postoperative Clinical improvement** | **Time to clinical deterioration (Avg, months)** | **Radiographic success (no progression)** | **Time to THA, months (% of total hips)** |
| Aigner 2002[26] | 45 | 69 |  Stage I: 67%Stage II: 20% Stage III: 13% | HHS |  Stage I: YESStage II: YESStage III: NO | 16 | (% out of ARCO Pre-Op Sub-groups):Stage I: 97%Stage II: 45%Stage III: 0% | Stage II: 46.5 (44%)Stage III: 16 (50%) |
| Beckmann 2013[28] | 12 | 13 | Stage II: 100% | HHSWOMACVASSF36 – PhysicalSF36- Mental | HHS -YESWOMAC-NOVAS-YESSF36 – Physical - YESSF36- Mental - YES | n/a | 83% | n/a |
| Bi 2019[30] | 36 | 26 | Stage II: 100% | HHS VAS | HHS – Yes; VAS - Yes | 26 | 72% (10/36 showed progression) | 26 (28%) |
| Gangji 2011[37] | 24 | 60 | Stage I:18%Stage II:82% | Lequesne IndexVASWOMAC | Lequesne Index-YESVAS -YESWOMAC-YES | no clinical deterioration | 27% | 26.5 (27%) |
| Haberal 2019[38] | 30 | 34 | Stage I: 13% Stage 2A: 10% Stage 2B: 7% Stage 2C: 17%Stage 3A: 10% Stage 3B: 3% Stage 3C: 33% Stage 4: 7%  | HHS VAS | HHS – NO | n/a | n/a | n/a (9%) |
| Hauzeur 2017[39] | 23 | 24 |  Stage I: 55.2% Stage II: 44.8% | HHSWOMACVAS | HHS- YESWOMAC-YESVAS-YES | no clinical deterioration | Evolution to ARCO stage IV was noted in 43% after 9.3 ± 2.2 months  | 8.2 (65.5%) |
| Kang 2018[45] | 53 | 48 | Stage I: 2% Stage II: 55% Stage III: 36% Stage IV: 7% | VAS | n/a | n/a | 59% (33/53 no progression) | 48 (49%) |
| Pepke 2016[60] | 14 | 24 | Stage II: 100% | HHSVAS | HHS- YESVAS-YES | n/a | (% out of ARCO Pre-Op Sub-groups):Group I – 43%Group II- 36% | n/a (37.5%) |
| Tabatabaee 2015[66] | 14 | 24 | Stage I: 14.2%Stage II: 50%Stage III: 35.7% | WOMACVAS | WOMAC - YESVAS - YES | n/a | n/a | n/a (21.4%) |
| Yan 2015[68] | 42 | 26 | Stage I: 5.8%Stage II: 94.1% | HHSVAS | HHS-YESVAS-YES | 12 | N/a | 12 (9.5%) |
| Yin 2016[69] | 26 | 36 | Stage I: 9%Stage IIA:3%Stage II B: 32%Stage II C:50%Stage IIIA:6% | HHSVAS |  HHS-YESVAS-YES | 22 | 42% -progressed | 14 (26.9%) |
| Nr – number of hips; Avg – average; THA – total hip replacement; n/a – not available; HHS – Harris Hip Score; VAS – visual analogue scale.  |